How to buy Intersect ENT stock

Intersect ENT, Inc is a medical devices business based in the US. Intersect ENT shares (XENT) are listed on the NASDAQ and all prices are listed in US Dollars. Intersect ENT employs 402 staff and has a trailing 12-month revenue of around USD$84.1 million.

How to buy shares in Intersect ENT

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Intersect ENT. Find the stock by name or ticker symbol: XENT. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Intersect ENT reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Intersect ENT, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Intersect ENT. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Intersect ENT share price

Use our graph to track the performance of XENT stocks over time.

Intersect ENT shares at a glance

• Key figures

Information last updated 2020-11-24.

52-week range	USD$5.97 - USD$31.46
50-day moving average	USD$17.3176
200-day moving average	USD$16.3178
Wall St. target price	USD$20.13
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.129

Buy Intersect ENT shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Intersect ENT stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Intersect ENT, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Intersect ENT financials

Revenue TTM	USD$84.1 million
Gross profit TTM	USD$87.4 million
Return on assets TTM	-20.89%
Return on equity TTM	-62.5%
Profit margin	-71.45%
Book value	$2.487
Market capitalisation	USD$629.5 million

TTM: trailing 12 months

Shorting Intersect ENT shares

There are currently 1.4 million Intersect ENT shares held short by investors – that's known as Intersect ENT's "short interest". This figure is 33.9% up from 1.0 million last month.

There are a few different ways that this level of interest in shorting Intersect ENT shares can be evaluated.

Intersect ENT's "short interest ratio" (SIR)

Intersect ENT's "short interest ratio" (SIR) is the quantity of Intersect ENT shares currently shorted divided by the average quantity of Intersect ENT shares traded daily (recently around 214952.30769231). Intersect ENT's SIR currently stands at 6.5. In other words for every 100,000 Intersect ENT shares traded daily on the market, roughly 6500 shares are currently held short.

However Intersect ENT's short interest can also be evaluated against the total number of Intersect ENT shares, or, against the total number of tradable Intersect ENT shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Intersect ENT's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Intersect ENT shares in existence, roughly 40 shares are currently held short) or 0.0431% of the tradable shares (for every 100,000 tradable Intersect ENT shares, roughly 43 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Intersect ENT.

Find out more about how you can short Intersect ENT stock.

Intersect ENT share dividends

We're not expecting Intersect ENT to pay a dividend over the next 12 months.

Have Intersect ENT's shares ever split?

Intersect ENT's shares were split on a 1:4 basis on 11 July 2014. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Intersect ENT shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Intersect ENT shares which in turn could have impacted Intersect ENT's share price.

Intersect ENT share price volatility

Over the last 12 months, Intersect ENT's shares have ranged in value from as little as $5.97 up to $31.46. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intersect ENT's is 1.5547. This would suggest that Intersect ENT's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Intersect ENT overview

Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.

Frequently asked questions

• What percentage of Intersect ENT is owned by insiders or institutions?

  Currently 2.753% of Intersect ENT shares are held by insiders and 89.396% by institutions.

• How many people work for Intersect ENT?

  Latest data suggests 402 work at Intersect ENT.

• When does the fiscal year end for Intersect ENT?

  Intersect ENT's fiscal year ends in December.

• Where is Intersect ENT based?

  Intersect ENT's address is: 1555 Adams Drive, Menlo Park, CA, United States, 94025

• What is Intersect ENT's ISIN number?

  Intersect ENT's international securities identification number is: US46071F1030

• What is Intersect ENT's CUSIP number?

  Intersect ENT's Committee on Uniform Securities Identification Procedures number is: 46071F103